BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wagner S, Mullins CS, Linnebacher M. Colorectal cancer vaccines: Tumor-associated antigens vs neoantigens. World J Gastroenterol 2018; 24(48): 5418-5432 [PMID: 30622371 DOI: 10.3748/wjg.v24.i48.5418] [Cited by in CrossRef: 50] [Cited by in F6Publishing: 46] [Article Influence: 12.5] [Reference Citation Analysis]
Number Citing Articles
1 Kye Y, Nagineni L, Gadad S, Ramirez F, Riva H, Fernandez L, Samaniego M, Holland N, Yeh R, Takigawa K, Dhandayuthapani S, Chacon J. The Identification and Clinical Applications of Mutated Antigens in the Era of Immunotherapy. Cancers 2022;14:4255. [DOI: 10.3390/cancers14174255] [Reference Citation Analysis]
2 Wang Y, Li C, Qi X, Yao Y, Zhang L, Zhang G, Xie L, Wang Q, Zhu W, Guo X. A Comprehensive Prognostic Analysis of Tumor-Related Blood Group Antigens in Pan-Cancers Suggests That SEMA7A as a Novel Biomarker in Kidney Renal Clear Cell Carcinoma. Int J Mol Sci 2022;23:8799. [PMID: 35955933 DOI: 10.3390/ijms23158799] [Reference Citation Analysis]
3 Jia W, Zhang T, Huang H, Feng H, Wang S, Guo Z, Luo Z, Ji X, Cheng X, Zhao R. Colorectal cancer vaccines: The current scenario and future prospects. Front Immunol 2022;13:942235. [DOI: 10.3389/fimmu.2022.942235] [Reference Citation Analysis]
4 Koustas E, Trifylli EM, Sarantis P, Papadopoulos N, Karapedi E, Aloizos G, Damaskos C, Garmpis N, Garmpi A, Papavassiliou KA, Karamouzis MV, Papavassiliou AG. Immunotherapy as a Therapeutic Strategy for Gastrointestinal Cancer-Current Treatment Options and Future Perspectives. Int J Mol Sci 2022;23:6664. [PMID: 35743107 DOI: 10.3390/ijms23126664] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Xie X, Song T, Feng Y, Zhang H, Yang G, Wu C, You F, Liu Y, Yang H. Nanotechnology-based multifunctional vaccines for cancer immunotherapy. Chemical Engineering Journal 2022;437:135505. [DOI: 10.1016/j.cej.2022.135505] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Le I, Dhandayuthapani S, Chacon J, Eiring AM, Gadad SS. Harnessing the Immune System with Cancer Vaccines: From Prevention to Therapeutics. Vaccines 2022;10:816. [DOI: 10.3390/vaccines10050816] [Reference Citation Analysis]
7 Dokht Khosravi A, Seyed-Mohammadi S, Teimoori A, Asarehzadegan Dezfuli A. The role of microbiota in colorectal cancer. Folia Microbiol (Praha) 2022. [PMID: 35534716 DOI: 10.1007/s12223-022-00978-1] [Reference Citation Analysis]
8 Cleyle J, Hardy MP, Minati R, Courcelles M, Durette C, Lanoix J, Laverdure JP, Vincent K, Perreault C, Thibault P. Immunopeptidomic analyses of colorectal cancers with and without microsatellite instability. Mol Cell Proteomics 2022;21:100228. [PMID: 35367648 DOI: 10.1016/j.mcpro.2022.100228] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
9 Lin H, Wang K, Xiong Y, Zhou L, Yang Y, Chen S, Xu P, Zhou Y, Mao R, Lv G, Wang P, Zhou D. Identification of Tumor Antigens and Immune Subtypes of Glioblastoma for mRNA Vaccine Development. Front Immunol 2022;13:773264. [PMID: 35185876 DOI: 10.3389/fimmu.2022.773264] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
10 Plundrich D, Chikhladze S, Fichtner-Feigl S, Feuerstein R, Briquez PS. Molecular Mechanisms of Tumor Immunomodulation in the Microenvironment of Colorectal Cancer. Int J Mol Sci 2022;23:2782. [PMID: 35269922 DOI: 10.3390/ijms23052782] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
11 Zhang J, Fan J, Skwarczynski M, Stephenson RJ, Toth I, Hussein WM. Peptide-Based Nanovaccines in the Treatment of Cervical Cancer: A Review of Recent Advances. IJN 2022;Volume 17:869-900. [DOI: 10.2147/ijn.s269986] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
12 Kim SH, Park HE, Jeong SU, Moon JH, Lee YR, Kim JK, Kong H, Park CS, Lee CK. Induction of Peptide-specific CTL Activity and Inhibition of Tumor Growth Following Immunization with Nanoparticles Coated with Tumor Peptide-MHC-I Complexes. Immune Netw 2021;21:e44. [PMID: 35036031 DOI: 10.4110/in.2021.21.e44] [Reference Citation Analysis]
13 Puleo J, Polyak K. A Darwinian perspective on tumor immune evasion. Biochim Biophys Acta Rev Cancer 2021;1877:188671. [PMID: 34933050 DOI: 10.1016/j.bbcan.2021.188671] [Reference Citation Analysis]
14 Boyne C, Lennox D, Beech O, Powis SJ, Kumar P. What Is the Role of HLA-I on Cancer Derived Extracellular Vesicles? Defining the Challenges in Characterisation and Potential Uses of This Ligandome. Int J Mol Sci 2021;22:13554. [PMID: 34948350 DOI: 10.3390/ijms222413554] [Reference Citation Analysis]
15 Roufarshbaf M, Esmaeil N, Akbari V. Comparison of four methods of colon cancer cell lysates preparation for ex vivo maturation of dendritic cells. Res Pharm Sci 2022;17:43-52. [PMID: 34909043 DOI: 10.4103/1735-5362.329925] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Hu LF, Lan HR, Huang D, Li XM, Jin KT. Personalized Immunotherapy in Colorectal Cancers: Where Do We Stand? Front Oncol 2021;11:769305. [PMID: 34888246 DOI: 10.3389/fonc.2021.769305] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
17 Wang D, Zhang H, Xiang T, Wang G. Clinical Application of Adaptive Immune Therapy in MSS Colorectal Cancer Patients. Front Immunol 2021;12:762341. [PMID: 34721435 DOI: 10.3389/fimmu.2021.762341] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
18 Aparicio C, Belver M, Enríquez L, Espeso F, Núñez L, Sánchez A, de la Fuente MÁ, González-Vallinas M. Cell Therapy for Colorectal Cancer: The Promise of Chimeric Antigen Receptor (CAR)-T Cells. Int J Mol Sci 2021;22:11781. [PMID: 34769211 DOI: 10.3390/ijms222111781] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
19 Roudko V, Cimen Bozkus C, Greenbaum B, Lucas A, Samstein R, Bhardwaj N. Lynch Syndrome and MSI-H Cancers: From Mechanisms to "Off-The-Shelf" Cancer Vaccines. Front Immunol 2021;12:757804. [PMID: 34630437 DOI: 10.3389/fimmu.2021.757804] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
20 Lee SW, Choi HY, Lee GW, Kim T, Cho HJ, Oh IJ, Song SY, Yang DH, Cho JH. CD8+ TILs in NSCLC differentiate into TEMRA via a bifurcated trajectory: deciphering immunogenicity of tumor antigens. J Immunother Cancer 2021;9:e002709. [PMID: 34593620 DOI: 10.1136/jitc-2021-002709] [Reference Citation Analysis]
21 Ye L, Wang L, Yang J, Hu P, Zhang C, Tong S, Liu Z, Tian D. Identification of Tumor Antigens and Immune Landscape in Glioblastoma for mRNA Vaccine Development. Front Genet 2021;12:701065. [PMID: 34527020 DOI: 10.3389/fgene.2021.701065] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
22 Sun H, Hu W, Yan Y, Zhang Z, Chen Y, Yao X, Teng L, Wang X, Chai D, Zheng J, Wang G. Using PAMPs and DAMPs as adjuvants in cancer vaccines. Hum Vaccin Immunother 2021;:1-12. [PMID: 34520322 DOI: 10.1080/21645515.2021.1964316] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
23 Ye L, Wang L, Yang J, Hu P, Zhang C, Tong S, Liu Z, Tian D. Identification of tumor antigens and immune subtypes in lower grade gliomas for mRNA vaccine development. J Transl Med 2021;19:352. [PMID: 34404444 DOI: 10.1186/s12967-021-03014-x] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
24 Mbugua SN, Njenga LW, Odhiambo RA, Wandiga SO, Onani MO. Beyond DNA-targeting in Cancer Chemotherapy. Emerging Frontiers - A Review. Curr Top Med Chem 2021;21:28-47. [PMID: 32814532 DOI: 10.2174/1568026620666200819160213] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
25 Moeinafshar A, Hemmati S, Rezaei N. Immunotherapy in AML: a brief review on emerging strategies. Clin Transl Oncol 2021. [PMID: 34160771 DOI: 10.1007/s12094-021-02662-1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
26 Chudasama R, Phung Q, Hsu A, Almhanna K. Vaccines in Gastrointestinal Malignancies: From Prevention to Treatment. Vaccines (Basel) 2021;9:647. [PMID: 34199248 DOI: 10.3390/vaccines9060647] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
27 Ma W, Pham B, Li T. Cancer neoantigens as potential targets for immunotherapy. Clin Exp Metastasis 2021. [PMID: 33950415 DOI: 10.1007/s10585-021-10091-1] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
28 Zhang Z, Lu M, Qin Y, Gao W, Tao L, Su W, Zhong J. Neoantigen: A New Breakthrough in Tumor Immunotherapy. Front Immunol 2021;12:672356. [PMID: 33936118 DOI: 10.3389/fimmu.2021.672356] [Cited by in Crossref: 1] [Cited by in F6Publishing: 26] [Article Influence: 1.0] [Reference Citation Analysis]
29 Du L, Cheng Q, Zheng H, Liu J, Liu L, Chen Q. Targeting stemness of cancer stem cells to fight colorectal cancers. Semin Cancer Biol 2021:S1044-579X(21)00041-9. [PMID: 33631296 DOI: 10.1016/j.semcancer.2021.02.012] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
30 Elmore LW, Greer SF, Daniels EC, Saxe CC, Melner MH, Krawiec GM, Cance WG, Phelps WC. Blueprint for cancer research: Critical gaps and opportunities. CA Cancer J Clin 2021;71:107-39. [PMID: 33326126 DOI: 10.3322/caac.21652] [Cited by in Crossref: 2] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
31 Roudko V, Bozkus CC, Orfanelli T, McClain CB, Carr C, O'Donnell T, Chakraborty L, Samstein R, Huang KL, Blank SV, Greenbaum B, Bhardwaj N. Shared Immunogenic Poly-Epitope Frameshift Mutations in Microsatellite Unstable Tumors. Cell 2020;183:1634-1649.e17. [PMID: 33259803 DOI: 10.1016/j.cell.2020.11.004] [Cited by in Crossref: 21] [Cited by in F6Publishing: 43] [Article Influence: 10.5] [Reference Citation Analysis]
32 Shahnazari M, Samadi P, Pourjafar M, Jalali A. Therapeutic vaccines for colorectal cancer: The progress and future prospect. Int Immunopharmacol 2020;88:106944. [PMID: 33182032 DOI: 10.1016/j.intimp.2020.106944] [Cited by in Crossref: 6] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
33 Soundara Rajan T, Gugliandolo A, Bramanti P, Mazzon E. In Vitro-Transcribed mRNA Chimeric Antigen Receptor T Cell (IVT mRNA CAR T) Therapy in Hematologic and Solid Tumor Management: A Preclinical Update. Int J Mol Sci 2020;21:E6514. [PMID: 32899932 DOI: 10.3390/ijms21186514] [Cited by in Crossref: 4] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
34 Leung KL, Verma D, Azam YJ, Bakker E. The use of multi-omics data and approaches in breast cancer immunotherapy: a review. Future Oncol 2020;16:2101-19. [PMID: 32857605 DOI: 10.2217/fon-2020-0143] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
35 Gonzalez-Villarreal CA, Quiroz-Reyes AG, Islas JF, Garza-Treviño EN. Colorectal Cancer Stem Cells in the Progression to Liver Metastasis. Front Oncol 2020;10:1511. [PMID: 32974184 DOI: 10.3389/fonc.2020.01511] [Cited by in Crossref: 6] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
36 Rus Bakarurraini NAA, Ab Mutalib NS, Jamal R, Abu N. The Landscape of Tumor-Specific Antigens in Colorectal Cancer. Vaccines (Basel) 2020;8:E371. [PMID: 32664247 DOI: 10.3390/vaccines8030371] [Cited by in Crossref: 1] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
37 Ciner AT, Jones K, Muschel RJ, Brodt P. The unique immune microenvironment of liver metastases: Challenges and opportunities. Semin Cancer Biol 2021;71:143-56. [PMID: 32526354 DOI: 10.1016/j.semcancer.2020.06.003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
38 Chruściel E, Urban-Wójciuk Z, Arcimowicz Ł, Kurkowiak M, Kowalski J, Gliwiński M, Marjański T, Rzyman W, Biernat W, Dziadziuszko R, Montesano C, Bernardini R, Marek-Trzonkowska N. Adoptive Cell Therapy-Harnessing Antigen-Specific T Cells to Target Solid Tumours. Cancers (Basel) 2020;12:E683. [PMID: 32183246 DOI: 10.3390/cancers12030683] [Cited by in Crossref: 20] [Cited by in F6Publishing: 13] [Article Influence: 10.0] [Reference Citation Analysis]
39 Yi M, Jiao D, Qin S, Chu Q, Li A, Wu K. Manipulating Gut Microbiota Composition to Enhance the Therapeutic Effect of Cancer Immunotherapy. Integr Cancer Ther 2019;18:1534735419876351. [PMID: 31517538 DOI: 10.1177/1534735419876351] [Cited by in Crossref: 9] [Cited by in F6Publishing: 20] [Article Influence: 4.5] [Reference Citation Analysis]
40 Sur D, Havasi A, Cainap C, Samasca G, Burz C, Balacescu O, Lupan I, Deleanu D, AlexandruIrimie. Chimeric Antigen Receptor T-Cell Therapy for Colorectal Cancer. J Clin Med 2020;9:E182. [PMID: 31936611 DOI: 10.3390/jcm9010182] [Cited by in Crossref: 13] [Cited by in F6Publishing: 25] [Article Influence: 6.5] [Reference Citation Analysis]
41 Jahanafrooz Z, Baradaran B, Mosafer J, Hashemzaei M, Rezaei T, Mokhtarzadeh A, Hamblin MR. Comparison of DNA and mRNA vaccines against cancer. Drug Discov Today 2020;25:552-60. [PMID: 31843577 DOI: 10.1016/j.drudis.2019.12.003] [Cited by in Crossref: 37] [Cited by in F6Publishing: 55] [Article Influence: 12.3] [Reference Citation Analysis]
42 Alexander PG, McMillan DC, Park JH. The local inflammatory response in colorectal cancer - Type, location or density? A systematic review and meta-analysis. Cancer Treat Rev 2020;83:101949. [PMID: 31869737 DOI: 10.1016/j.ctrv.2019.101949] [Cited by in Crossref: 10] [Cited by in F6Publishing: 15] [Article Influence: 3.3] [Reference Citation Analysis]
43 Rajayi H, Tavasolian P, Rezalotfi A, Ebrahimi M. Cancer Stem Cells Targeting; the Lessons from the Interaction of the Immune System, the Cancer Stem Cells and the Tumor Niche. International Reviews of Immunology 2019;38:267-83. [DOI: 10.1080/08830185.2019.1669593] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
44 Li A, Yi M, Qin S, Chu Q, Luo S, Wu K. Prospects for combining immune checkpoint blockade with PARP inhibition. J Hematol Oncol 2019;12:98. [PMID: 31521196 DOI: 10.1186/s13045-019-0784-8] [Cited by in Crossref: 43] [Cited by in F6Publishing: 58] [Article Influence: 14.3] [Reference Citation Analysis]
45 Jiang S, Good D, Wei MQ. Vaccinations for Colorectal Cancer: Progress, Strategies, and Novel Adjuvants. Int J Mol Sci 2019;20:E3403. [PMID: 31373300 DOI: 10.3390/ijms20143403] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
46 Advani S, Kopetz S. Ongoing and future directions in the management of metastatic colorectal cancer: Update on clinical trials. J Surg Oncol 2019;119:642-52. [PMID: 30852840 DOI: 10.1002/jso.25441] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 5.7] [Reference Citation Analysis]
47 [DOI: 10.1101/662262] [Cited by in Crossref: 8] [Cited by in F6Publishing: 1] [Reference Citation Analysis]